Cabaletta Bio (NASDAQ: CABA)
$1.55
(3.3%)
$0.05
Price as of August 5, 2025, 4:00 p.m. ET
Cabaletta Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cabaletta Bio Company Info
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.